What Is NGS Testing for Cancer? Benefits, Importance & Treatment

What Is NGS Testing for Cancer? Benefits, Importance & Treatment

For decades, cancer treatment was bound by anatomy, where the tumour lived dictated how it was treated. But looking at cancer purely through an imaging scan leaves a massive blind spot. It fails to explain why two tumours that look identical under a microscope will react in totally opposite ways to the same chemotherapy. The variation is hidden in the molecular engine driving the tumour’s growth.

NGS testing for cancer was built to close that gap. Next-generation sequencing identifies specific DNA mutations and alterations driving the tumour. Unlike older methods that tested one mutation at a time, a single NGS panel scans hundreds of cancer-related genes in one run. This gives oncologists a detailed genetic portrait of the tumour before they decide on treatment.^{<a href=”https://ascopubs.org/doi/10.1200/PO.22.00715″>1</a>}

What Is NGS Testing for Cancer?

NGS testing is a molecular diagnostic tool that sequences large portions of a tumour’s DNA. It produces a detailed map of mutations, gene fusions, copy number changes, and other alterations. This detects findings that older single-gene tests would miss unless specifically designed to look for them.

It goes by several names: comprehensive genomic profiling, next-generation sequencing cancer analysis, or simply tumour profiling.² The scope of the panel determines how many genes are examined.

How Does NGS Testing Work in Cancer Diagnosis?

Usually, a sample of tumour tissue from a biopsy or surgery is taken. DNA is extracted from that sample, broken into fragments, tagged with chemical markers, and fed into a sequencing instrument.

A bioinformatics pipeline then assembles those readings, compares them to a reference genome, and flags the differences.² The output is not just a list of mutations, but a structured report. It highlights clinically relevant alterations and helps oncologists make treatment decisions.

DNA Sequencing Process Explained

The DNA sequencing cancer analysis step is more complex than it appears. The tumour sample must meet minimum quality and quantity standards.³ Degraded tissue, particularly from older formalin-fixed blocks, can produce incomplete results.

After sequencing, the data is aligned and filtered. Clinically relevant variants are flagged, while variants of uncertain significance are reported separately.

Types of Mutations Detected

NGS panels are designed to detect several categories of genetic changes:

• Single nucleotide variants (SNVs): Point mutations where one DNA base is substituted for another.⁴
• Insertions and deletions (indels): Small additions or removals in the DNA sequence.⁴
• Gene fusions: Two separate genes join abnormally, a hallmark of certain leukaemias and a subset of lung cancers.⁴
• Microsatellite instability (MSI) and tumour mutational burden (TMB): Markers used to assess whether a patient is likely to respond to immunotherapy.⁴

Additional genomic biomarkers may also be included based on the specific cancer type and the customised sequencing panel chosen for the patient.

What Are The Benefits of NGS Testing in Cancer Treatment?

NGS does more than find mutations. It makes the diagnostic evaluation more efficient and comprehensive, ultimately supporting better patient care and treatment outcomes.

• A single NGS test replaces multiple sequential single-gene tests. That means fewer delays between biopsy and treatment decision.⁵
• Tumour biopsies are often small. Running several individual tests on a limited sample risks exhausting it before a clear answer is found. NGS extracts more information from less material.⁵
• Standard single-gene panels only detect what they are designed to look for. NGS scans the full picture.⁵
• For patients with advanced cancer who have not responded to first-line treatment, this matters most. A mutation linked to an approved targeted therapy, or an open clinical trial, can show up on an NGS report when a narrower test would have missed it entirely. The result is a faster, more complete picture with less material used.⁵

How NGS Helps Identify Targeted Therapy Options?

Targeted therapy works by blocking the abnormal proteins or signals that cause cancer cells to grow and multiply.  For a targeted drug to work, the matching genetic change must be present in the patient’s tumour sample, and that is what NGS confirms.

For example, a non-small cell lung cancer (NSCLC) patient with an EGFR exon 19 deletion responds well to a targeted drug called osimertinib. Meanwhile, a patient with an ALK gene alteration responds better to alectinib.⁶

These are completely different drugs for what looks like the same type of cancer. Without NGS, the oncologist would have to guess or run multiple individual tests sequentially, losing time in the process.

What Is Personalised Cancer Treatment Using Genomics?

Precision oncology goes further than matching one drug to a specific gene variant or biomarker, or stratifying the patient risk using genomic signatures and selecting the personalised drug for treatment. The full genomic profile of a tumour can reveal co-occurring mutations. Personalised cancer treatment using genomics allows oncologists to plan across treatment lines, not just the first one.⁷

Knowing the baseline genomic landscape helps anticipate which resistance mechanisms are most likely, so the next treatment is already being considered.

What Are the Types of Cancers That Use NGS Testing?

NGS testing is now part of standard oncology workups across a wide range of malignancies. Cancers where NGS testing is commonly used:

• Lung cancer (especially non-small cell)⁶
• Breast cancer (BRCA1/2, PIK3CA alterations)⁶
• Colorectal cancer (KRAS, NRAS, BRAF mutations; MSI status)⁶
• Ovarian cancer⁶
• Melanoma (BRAF V600E mutation)⁶
• Leukaemias and lymphomas⁶

What is the Difference Between NGS vs Traditional Cancer Testing Methods?

Traditional tests are efficient and include histopathology (examining tissue samples under a microscope) and specific molecular techniques like immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH). These traditional methods are focused and targeted.

They work well for checking known proteins or specific gene rearrangements, making them practical for routine diagnostic workflows due to their speed and lower cost. However, because they only look for predetermined markers, they cannot detect unexpected or rare genetic alterations.⁸

NGS takes a broader, data-driven approach by sequencing hundreds of genes simultaneously. Instead of testing one marker at a time, a single NGS panel evaluates multiple genetic changes at once, including rare mutations that IHC or FISH might miss. This comprehensive view reduces the need for repeated tissue biopsies and provides a fuller genomic landscape. This helps oncologists find alternative targeted options when standard testing methods yield incomplete answers.⁸

What Are the Limitations of NGS Testing?

Turnaround time is a key limitation. Results can take a few weeks, which is not ideal in aggressive cancers. Also, not every detected mutation has a matching therapy, and some findings remain of uncertain significance.⁵

Another challenge is tumour heterogeneity. A single biopsy reflects only one part of the tumour at one moment. Mutations in other regions or metastatic sites may be missed, though liquid biopsy can partly help address this.⁵

Who Should Consider NGS Testing?

NGS testing is valuable at multiple stages of cancer care, from early diagnosis through advanced disease:

• Patients newly diagnosed with cancer: Testing at diagnosis helps identify actionable genetic drivers right away, allowing oncologists to choose the most effective targeted therapy or immunotherapy as a first-line treatment.
• Patients with advanced, metastatic, or recurrent cancer: If cancer has spread or stopped responding to standard treatments, NGS can uncover alternative targeted options or clinical trials based on the tumour’s genetic profile.
• Individuals with a personal or family history of cancer: Beyond testing the tumour itself (somatic testing), NGS is used for hereditary (germline) genetic testing. This identifies inherited mutations, such as BRCA1, BRCA2, or Lynch syndrome genes, helping both patients and their blood relatives understand and manage their hereditary cancer risk.

What is the Cost and Availability of NGS Testing in India?

In India, the cost of NGS testing has come down in the last few years. A lot of diagnostic labs now offer comprehensive panels for less than 1 lakh rupees, though prices still vary a lot depending on the number of genes covered in the panel and the provider.

You can get tested at major cancer centres and specialised diagnostic labs in Bengaluru, Hyderabad, Mumbai, Chennai, and Delhi. Some insurance policies that include oncology diagnostics cover part of the cost, though patients should verify this directly with their insurer before testing.

What is the Future of Genomic Testing in Cancer Care?

Liquid biopsy is probably the most significant near-term development in cancer genomics. It uses cell-free tumour DNA circulating in the blood, avoiding the need for repeated tissue biopsies.⁹

This makes it possible to monitor a tumour’s genomic evolution over the course of treatment in a way that was not feasible before. AI-assisted interpretation tools are also improving the speed and accuracy with which complex NGS reports are translated into clinical recommendations.⁹

What If NGS Does Not Find a Targetable Mutation?

Not every NGS report comes back with a clear molecular target. A negative result still carries clinical value. It redirects the oncologist toward other evidence-based options, whether that is immunotherapy, a chemotherapy regimen suited to the cancer type, or enrollment in a clinical trial with different eligibility criteria. Sometimes the absence of a targeted mutation is itself informative.²

Conclusion

NGS testing reflects the complexity of cancer biology by moving diagnosis away from anatomical location alone and toward a more precise, mutation-based framework.

By identifying the particular genetic alterations in a tumour, therapy options are shifted from location and stage to a more accurate, biology-based approach. As genomic profiling becomes more integrated into routine oncology care, platforms like MedGenome are helping clinicians translate complex NGS data into treatment decisions grounded in tumour biology.

Frequently Asked Questions

 

1. How does NGS help identify targeted therapy?

NGS maps the mutations present in a tumour. Oncologists use that map to match the patient to approved targeted drugs or clinical trials.

2. Is NGS testing used for all cancers?

It is most commonly used for advanced solid tumours and cancers that have relapsed. Use in early-stage and common cancers is growing as costs fall, but it is not yet universal.

3. Can NGS testing guide immunotherapy decisions?

Yes. Panels assess TMB and MSI status, both of which are established predictors of response to checkpoint inhibitors like pembrolizumab. Without these markers, immunotherapy eligibility is harder to assess accurately.

 4. What sample is used for NGS testing?

A biopsy from the tumour tissue is the standard. Liquid biopsy using a blood draw is an alternative when tissue is not accessible.

5. How long do NGS cancer test results take?

Most results come back within one to three weeks. The timeline is based on the lab, the panel, and sample quality.

6. Is NGS better than single-gene testing?

Generally yes. NGS provides a broader, more comprehensive picture that a single-gene test cannot match. That said, when only one specific, high-frequency mutation needs rapid confirmation, single-gene tests remain faster and cheaper. The right choice depends on the clinical question.

References

1. Gibbs, Sarah N., Desi Peneva, Gebra C. Carter, Melanie R. Palomares, Snehal Thakkar, David W. Hall, H Dalglish, Cynthia C., and I Yermilov. 2023. “Comprehensive Review on the Clinical Impact of Next-Generation Sequencing Tests for the Management of Advanced Cancer.” JCO Precision Oncology 7 (7): e2200715.
   https://ascopubs.org/doi/10.1200/PO.22.00715
2. Ghoreyshi, Nima, R Heidari, Arezoo Farhadi, M Chamanara, Nastaran F., Mahmood Vahidi, and J Behroozi. 2025. “Next-generation Sequencing in Cancer Diagnosis and Treatment: Clinical Applications and Future Directions.” Discover Oncology 16 (1): 578. https://link.springer.com/article/10.1007/s12672-025-01816-9
3. Okojie, Jeffrey, Nikole O’Neal, Mackenzie Burr, P Worley, Isaac Packer, DeLaney Anderson, Jack D., et al. 2024. “DNA Quantity and Quality Comparisons Between Cryopreserved and FFPE Tumours From Matched Pan-Cancer Samples.” Current Oncology 31 (5): 2441–52. https://www.mdpi.com/1718-7729/31/5/183
4. Palmeri, M., J. Mehnert, A.W. Silk, S.K. Jabbour, S. Ganesan, P. Popli, G. Riedlinger, et al. 2021. “Real-world Application of Tumour Mutational Burden-high (TMB-high) and Microsatellite Instability (MSI) Confirms Their Utility as Immunotherapy Biomarkers.” ESMO Open 7 (1): 100336.
   https://www.sciencedirect.com/science/article/pii/S2059702921002982
5. Isaic, A., Motofelea, N., Hoinoiu, T., Motofelea, A. C., Leancu, I. C., Stan, E., Gheorghe, S. R., Dutu, A. G., & Crintea, A. (2025). Next-Generation Sequencing: A Review of Its Transformative Impact on Cancer Diagnosis, Treatment, and Resistance Management. Diagnostics (Basel, Switzerland), 15(19), 2425.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC12523276/
6. Kulda, Vlastimil, Jiri Polivka, Martin Svaton, T Vanecek, Marcela Buresova, Katerina Houfkova, Mahyar S. Bagheri, et al. 2023. “Next Generation Sequencing Analysis and Its Benefit for Targeted Therapy of Lung Adenocarcinoma.” Cancer Genomics & Proteomics 20 (4): 404–11.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC10320561/
7. Pfohl, Ulrike, Alina Pflaume, M. Regenbrecht, Sabine Finkler, Quirin G. Adelmann, Christoph Reinhard, Christian Regenbrecht, and L. Wedeken. 2021. “Precision Oncology Beyond Genomics: The Future Is Here—It Is Just Not Evenly Distributed.” Cells 10 (4): 928. https://pmc.ncbi.nlm.nih.gov/articles/PMC8072767/
8. De Biase, Dario, Giorgia Acquaviva, Michela Visani, Viviana S., Chiara M. Argento, Antonio De Leo, T Maloberti, Annalisa Pession, and Giovanni Tallini. 2020. “Molecular Diagnostic of Solid Tumour Using a Next Generation Sequencing Custom-Designed Multi-Gene Panel.” Diagnostics 10 (4): 250.  https://www.mdpi.com/2075-4418/10/4/250
9. Ma, Liwei, Huiling Guo, Yunxiang Zhao, Zhibo Liu, Chenran Wang, Jiahao Bu, Ting Sun, and Jianwei Wei. 2024. “Liquid Biopsy in Cancer: Current Status, Challenges and Future Prospects.” Signal Transduction and Targeted Therapy 9 (1): 336.
   https://www.nature.com/articles/s41392-024-02021-w